Details of the Drug
General Information of Drug (ID: DMGXM9C)
| Drug Name | 
                     4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide 
                 | 
            ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                                         
                        CHEMBL22374; ST50982048; 1-phenyl-3-[2-(4-sulfamoylphenyl)ethyl]urea; 10080-04-3; AC1N65GX; CTK0G8621; aromatic sulfonamide compound 21; BDBM16656; DTXSID80401056; ZINC6344454; AKOS024355000; 1-(4-Sulfamoylphenethyl)-3-phenylurea; MCULE-8492301896; N-(4-aminosulfonylphenylethyl)-N'-phenyl-urea; N-phenyl{[2-(4-sulfamoylphenyl)ethyl]amino}carboxamide; Benzenesulfonamide, 4-[2-[[(phenylamino)carbonyl]amino]ethyl]-
                        
                     
                                     | 
            ||||||||||||||||||||||
| Indication | 
                                                            
  | 
            ||||||||||||||||||||||
| Drug Type | 
                     Small molecular drug 
                 | 
            ||||||||||||||||||||||
| Structure | 
                    ![]()  | 
            ||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 319.4 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers | 
                        
  | 
                ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||||||||
                    
  | 
            ||||||||||||||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||||||||||||||


